Adam Lowy, MD
Psychiatry · Venice, CANPI 1871505537
Payments from drug & device makers
Across 1,016 payments — averaging $799.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$608K
- Alkermes, Inc.$134K
- Teva Pharmaceuticals USA, Inc.$52K
- Otsuka America Pharmaceutical, Inc.$18K
- AbbVie$188
- Otsuka Pharmaceutical Development & Commercialization, Inc.$101
- plus $117 from 6 others
What the payments were for
- Consulting fees$64,1218%
- Speaking & faculty fees$665,79082%
- Travel & lodging$61,5548%
- Food & beverage$20,3663%
- Education$560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 706 | $608,259 |
| Alkermes, Inc. | 176 | $133,628 |
| Teva Pharmaceuticals USA, Inc. | 73 | $52,221 |
| Otsuka America Pharmaceutical, Inc. | 47 | $17,584 |
| AbbVie(2 entities) | 4 | $188 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $101 |
| Merz Pharmaceuticals, LLC | 1 | $28 |
| Vanda Pharmaceuticals Inc. | 2 | $25 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Organogenesis Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| Lundbeck LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$598,466
- ARISTADA$396,015
- LYBALVI$139,730
- ARISTADA INITIO$87,181
- AUSTEDO$50,626
- ABILIFY MAINTENA$16,655
- REXULTI$724
- VRAYLAR$125
- UZEDY$116
How this compares
$812,098 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 13 | $6,429 |
| Lurasidone Hcl | 14 | $995 |
| Trazodone Hcl | 65 | $618 |
| Duloxetine Hcl | 29 | $546 |
| Buspirone Hcl | 40 | $499 |
| Doxepin Hcl | 11 | $489 |
| Risperidone | 25 | $372 |
| Escitalopram Oxalate | 60 | $332 |
| Bupropion Hcl SrBupropion Hcl | 25 | $320 |
| Quetiapine Fumarate | 26 | $304 |
| Citalopram HbrCitalopram Hydrobromide | 22 | $302 |
| Divalproex Sodium | 16 | $299 |
| Propranolol Hcl | 15 | $223 |
| Sertraline Hcl | 25 | $208 |
| Mirtazapine | 18 | $79 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Venice
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.